DA01 Dopaminergic Neurons and GDNF Gene Therapy Studies Underway for Parkinson Disease

Bayer provided an update on trials currently underway for the treatment of PD by its subsidiaries.

Targeting Dysfunctional RNA for a More Precise Approach to Gene Therapy

Locanabio CEO James Burns, PhD, discusses the firm's targeted approach to treating genetic disorders of the central nervous system and the eye.

FDA Accepts IND for Limb-Girdle Muscular Dystrophy Gene Therapy

Asklepios BioPharmaceuticals noted that it plans to initiate dosing for the LION-101 phase 1/2 clinical trial in the first half of 2022.